Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition

Histopathology

Volumn 43, Issue 1, 2003, Pages 26-32

  Piek, J M J ^a   Verheijen, R H M ^a   Menko, F H ^a   Jongsma, A P M ^a   Weegenaar, J ^a   Gille, J J P ^a   Pals, G ^a   Kenemans, P ^a   Van Diest, Paul J ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Pathology ^*  (Netherlands)

Author keywords

BRCA1; Carcinogenesis; Ovary; Proliferation differentiation

Indexed keywords

CYCLIN A; CYCLIN D; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER LOCALIZATION; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM DYSPLASIA; EPITHELIUM HYPERPLASIA; FEMALE; HERITABILITY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; OVARIECTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE FIXATION; TISSUE SECTION; VITAL STAIN;

ADNEXAL DISEASES; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

FALLOPIA;

EID: 0037897665     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01654.x     Document Type: Article

References (25)

1. Scully RE. Pathology of ovarian cancer precursors. J. Cell Biochem. Suppl. 1995: 23; 208-218.
2. Fox H. Pathology of early malignant change in the ovary. Int. J. Gynecol. Pathol. 1993: 12; 153-155.
3. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001: 38; 87-95.
4. Deligdisch L, Gil J, Kerner H, Wu HS, Beck D, Gershoni-Baruch R. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 1999: 86; 1544-1550.
5. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum. Pathol. 1999: 30; 151-157.
6. Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl Cancer Inst. 1996: 88; 1810-1820.
7. Auersperg N, Maines-Bandiera SL, Dyck HG. Ovarian carcinogenesis and the biology of ovarian surface epithelium. J. Cell Physiol. 1997: 173; 261-265.
8. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001: 195; 451-456.
9. Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol. 2000: 76; 45-50.
10. Michalides RJ. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J. Clin. Pathol. 1999: 52; 555-568.
11. Resta L, De Benedictis G, Scordari MD, Orlando E, Borraccino V, Milillo F. Hyperplasia and metaplasia of ovarian surface epithelium in women with endometrial carcinoma. Suggestion for a hormonal influence in ovarian carcinogenesis. Tumori 1987: 73; 249-256.
12. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet. Gynecol. 1993: 82; 181-186.
13. Deligdisch L, Einstein AJ, Guera D, Gil J. Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer 1995: 76; 1027-1034.
14. Stratton JF, Buckley CH, Lowe D, Ponder BA. Comparison of prophylactic oophorectomy specimens from carriers and non-carriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J. Natl Cancer Inst. 1999: 91; 626-628.
15. Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol. Oncol. 2000: 78; 278-287.
16. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int. J. Gynaecol. Obstet. 1995: 49 (Suppl.); S9-15.
17. Wong AS, Leung PC, Maines-Bandiera SL, Auersperg N. Metaplastic changes in cultured human ovarian surface epithelium. In Vitro Cell Dev. Biol. Anim. 1998: 34; 668-670.
18. Yu WC, Leung BS, Gao YL. Effects of 17 beta-estradiol on progesterone receptors and the uptake of thymidine in human breast cancer cell line CAMA-1. Cancer Res. 1981: 41; 5004-5009.
19. Werness BA, Afify AM, Eltabbakh GH, Huelsman K, Piver MS, Paterson JM. p53, c-erbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. Int. J. Gynecol. Pathol. 1999: 18; 338-343.
20. Zweemer RP, Shaw PA, Verheijen RM et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J. Clin. Pathol. 1999: 52; 372-375.
21. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995: 27; 367-371.
22. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 2001: 11; 119-129.
23. Barbieri F, Cagnoli M, Ragni N et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin. Cancer Res. 1999: 5; 1837-1842.
24. Hung WC, Chai CY, Huang JS, Chuang LY. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum. Pathol. 1996: 27; 1324-1328.
25. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol. Oncol. 1997: 64; 189-195.